查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008753

生物标记技术市场报告：按检测类型、适应症、产品类型、技术、应用和地区划分（2026-2034 年）

Biomarker Technologies Market Report by Test Type, Indication, Product, Technology (Polymerase Chain Reaction, Next Generation Sequencing, Immunoassay, and Others), Application, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

全球生物标记技术市场在2025年达到500亿美元。展望未来，IMARC集团预测，到2034年，该市场将达到1,294亿美元，2026年至2034年的复合年增长率为10.80%。该市场正经历稳定成长，其成长动力来自医疗保健、製药和诊断领域应用范围的扩大，以及人们对精准医疗和疾病检测日益增长的兴趣，以及对非侵入性诊断方法的需求不断增长。

生物标誌物技术市场的发展趋势：

精准医疗的需求日益增长

精准医疗需求的日益增长是生物标记技术市场的主要驱动力。精准医疗代表医疗保健领域的模式转移，旨在根据患者独特的基因、分子和临床特征提供个人化的治疗策略。生物标誌物在这一转变中发挥着至关重要的作用。生物标誌物是反映体内各种生物过程的可测量指标。在精准医疗的背景下，生物标记是识别特定疾病亚型、预测疾病进展和确定最有效治疗方法的重要工具。透过分析生物标誌物，医疗专业人员可以为每位患者量身定制治疗性介入，优化治疗效果，同时最大限度地减少潜在的副作用。精准医疗最吸引人的方面之一是其革新癌症治疗的潜力。生物标记技术使肿瘤学家能够识别肿瘤内的基因突变和蛋白质标记物，从而选择针对癌症潜在分子因素的标靶治疗。这提高了治疗成功率，减少了试验错疗法的必要性，使患者避免无效治疗和不必要的毒性，并最终促进了市场成长。

体学技术的进步

体学技术的进步是生物标记技术市场的另一个重要驱动力。体学涵盖基因组学、蛋白质组学和代谢体学等多个科学领域，每个领域都在生物标记的发现和开发中发挥着至关重要的作用。基因组学研究个体的全部DNA序列，从而深入了解与疾病相关的基因变异和突变。 DNADNA测序技术的不断进步使得基因组分析更加快速高效，并降低了成本，进而鑑定出众多与各种疾病相关的遗传生物标记。这些丰富的基因组数据拓展了个人化医疗和标靶治疗开发的可能性。蛋白质体学专注于研究生物系统中的蛋白质。质谱和其他创新的蛋白质组学技术使研究人员能够识别与疾病和治疗反应相关的特定蛋白质生物标记。这些生物标记在改善疾病诊断、监测和药物研发方面具有巨大的潜力。代谢体学分析生物检体中的小分子和代谢物，以阐明代谢途径及其异常。因此，体学技术的进步不断丰富生物标记工具箱，促进新生物标记的发现，加深我们对疾病的理解，并推动诊断和药物发现的创新。

慢性疾病负担日益加重

慢性疾病负担日益加重是生物标记技术市场成长的关键驱动因素。心血管疾病、糖尿病、癌症和呼吸系统疾病等慢性疾病构成日益严峻的全球健康挑战。人口老化、生活方式改变和环境因素等都导致了这些疾病盛行率的上升。生物标记技术已成为对抗慢性疾病的重要工具。它们具有早期精准检测的潜力，这对于有效疾病管理和改善患者预后至关重要。生物标记能够识别体内细微的变化，这些变化提示慢性疾病的发生或进展，甚至在临床症状出现之前即可发现。这种早期检测使医疗专业人员能够迅速介入，实施个人化治疗方案，并更密切地监测疾病进展。随着全球慢性疾病负担的持续加重，对支持早期检测、精准监测和个人化治疗策略的生物标记技术的需求也日益增长。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球生物标记技术市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依测试类型划分

  • 固态切片检查
  • 液态切片

第七章 市场区隔：依适应症划分

  • 癌症
  • 感染疾病
  • 自体免疫疾病
  • 心血管疾病
  • 其他的

第八章 市场区隔：依产品划分

  • 消耗品
  • 侦测
  • 试剂
  • 装置

第九章 市场区隔：依技术划分

  • 聚合酵素链锁反应（PCR）
  • 次世代定序（NGS）
  • 免疫检测
  • 其他的

第十章 市场区隔：依应用领域划分

  • 药物发现
  • 临床诊断
  • 个人化医疗

第十一章 市场区隔：按地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十二章 SWOT 分析

第十三章：价值链分析

第十四章：波特五力分析

第十五章：价格分析

第十六章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • Illumina Inc.
    • LI-COR Inc.
    • Merck KGaA
    • PerkinElmer Inc.
    • QIAGEN NV
    • Shimadzu Corporation
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
Product Code: SR112026A4341

The global biomarker technologies market size reached USD 50.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 129.4 Billion by 2034, exhibiting a growth rate (CAGR) of 10.80% during 2026-2034. The market is experiencing steady growth, driven by increasing applications in healthcare, pharmaceuticals, and diagnostics, coupled with a heightening focus on precision medicine and disease detection and the rising demand for non-invasive diagnostic methods.

BIOMARKER TECHNOLOGIES MARKET ANALYSIS:

  • Market Growth and Size: The market is currently witnessing stable growth, fueled by its increasing applications in healthcare, pharmaceuticals, and diagnostics. Additionally, the integration of biomarker technologies into research and development (R&D) processes further fuels this stable growth, enhancing their pivotal role in advancing healthcare, pharmaceuticals, and diagnostics.
  • Rising Demand for Non-Invasive Diagnostic Methods: The market witnesses an increasing demand for non-invasive diagnostic methods, driven by their patient-friendly nature, accuracy, and effectiveness in detecting diseases without the need for invasive procedures.
  • Industry Applications: The market is experiencing high demand from diverse industries, including healthcare, pharmaceuticals, and diagnostics, highlighting their versatility and widespread adoption.
  • Geographical Trends: North America leads the biomarker technologies market due to its robust infrastructure, significant investments in research and development, and a strong focus on healthcare innovation.
  • Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation and expanding their market share, resulting in continuous advancements in biomarker technology.
  • Challenges and Opportunities: While regulatory hurdles present challenges, it also promises of personalized medicine and diagnostic breakthroughs that offers exciting opportunities for industry players.
  • Future Outlook : The future of the biomarker technologies market looks promising, especially in the realms of personalized medicine and enhanced disease detection.

BIOMARKER TECHNOLOGIES MARKET TRENDS:

Growing demand for precision medicine

The growing demand for precision medicine is a maior driving force in the biomarker technologies market. Precision medicine represents a paradigm shift in healthcare, aiming to provide personalized treatment strategies for patients based on their unique genetic, molecular, and clinical characteristics. Biomarkers play a pivotal role in this transformation. They are measurable indicators that reflect various biological processes within the body. In the context of precision medicine, they serve as crucial tools for identifying specific disease subtypes, predicting disease progression, and determining the most effective treatment approaches. By analyzing biomarkers, healthcare professionals can tailor interventions to individual patients, optimizing therapeutic outcomes while minimizing potential side effects. One of the most compelling aspects of precision medicine is its potential to revolutionize cancer care. Biomarker technologies allow oncologists to identify genetic mutations and protein markers in tumors, enabling the selection of targeted therapies that specifically address the underlying molecular drivers of cancer. This increases the chances of successful treatment and reduces the need for trial-and-error approaches, sparing patients from ineffective therapies and unnecessary toxicity, thereby fueling market growth.

Advancements in omics technologies

Advancements in omics technologies represent another significant driver in the biomarker technologies market. Omics encompasses various scientific disciplines, including genomics, proteomics, and metabolomics, each of which plays a crucial role in biomarker discovery and development. Genomics involves the study of an individual's complete set of DNA, providing insights into genetic variations and mutations associated with diseases. Ongoing advancements in DNA sequencing technologies have made it faster and more cost-effective to analyze the genome, leading to the identification of numerous genetic biomarkers linked to various conditions. This wealth of genomic data expands the potential for personalized medicine and the development of targeted therapies. Proteomics focuses on the study of proteins within biological systems. Mass spectrometry and other innovative proteomic techniques enable researchers to identify specific protein biomarkers associated with diseases or treatment responses. These biomarkers hold immense promise for improving disease diagnosis, monitoring, and drug development. Metabolomics examines the small molecules and metabolites in biological samples, shedding light on metabolic pathways and dysregulations. As a result, advancements in omics technologies continue to enrich the biomarker toolbox, facilitating the discovery of new biomarkers, enhancing our understanding of diseases, and driving innovation in diagnostics and drug development.

Increasing burden of chronic diseases

The escalating burden of chronic diseases is a significant factor propelling the growth of the biomarker technologies market. Chronic diseases, such as cardiovascular diseases, diabetes, cancer, and respiratory disorders, are a growing global health challenge. Factors like aging populations, lifestyle changes, and environmental factors contribute to the increasing prevalence of these conditions. Biomarker technologies have emerged as critical tools in the battle against chronic diseases. They offer the potential for early and accurate detection, which is crucial for effective disease management and improved patient outcomes. Biomarkers can identify subtle changes in the body that may indicate the onset or progression of a chronic disease, often before clinical symptoms manifest. This early detection empowers healthcare professionals to intervene promptly, implement personalized treatment plans, and monitor disease progression more closely. As the burden of chronic diseases continues to rise globally, there has been a heightened demand for biomarker technologies that support early detection, precise monitoring, and personalized treatment strategies.

BIOMARKER TECHNOLOGIES INDUSTRY SEGMENTATION:

Breakup by Test Type:

  • Solid Biopsy
  • Liquid Biopsy

Liquid biopsy accounts for the majority of the market share

Liquid biopsy has emerged as a transformative force in the biomarker technologies market. This non-invasive method involves analyzing biomarkers present in bodily fluids, such as blood or urine, to detect diseases, particularly cancer. Liquid biopsies offer numerous advantages, including early disease detection, real-time monitoring, and the ability to track treatment response. They reduce the need for invasive procedures and provide valuable information on tumor heterogeneity. As the demand for less invasive and more accessible diagnostic methods increases, liquid biopsies are driving the market further by expanding applications beyond traditional tissue-based biopsies and revolutionizing the field of diagnostics. Their potential to improve patient care and outcomes makes them a key market driver.

Solid biopsy methods involve the extraction of tissue samples from tumors or other abnormal growths for analysis. Solid biopsies provide essential biomarker data that guide treatment decisions, especially in cancer care. They also enable the identification of specific genetic, protein, or molecular markers, aiding in the selection of targeted therapies and predicting treatment responses. As precision medicine gains prominence, solid biopsy-derived biomarkers become indispensable, contributing to the market growth. Advancements in solid biopsy techniques, such as minimally invasive procedures, improve patient comfort and further fuel their adoption rate.

Breakup by Indication:

  • Cancer
  • Infectious Diseases
  • Autoimmune Disorders
  • Cardiovascular Disorders
  • Others

Cancer holds the largest share in the industry

Biomarker technologies are instrumental in the fight against cancer, providing essential tools for early detection, precise diagnosis, and tailored treatment strategies. They enable the identification of specific genetic and molecular markers, improving patient outcomes and driving substantial market growth in the oncology sector. They also play a crucial role in infectious disease management by facilitating rapid and accurate pathogen detection, monitoring treatment responses, and aiding in epidemiological studies, contributing significantly to the market's expansion, particularly in the context of global health crises.

Biomarker technologies are pivotal in diagnosing and monitoring autoimmune disorders, offering insights into disease progression and treatment efficacy, thus driving their adoption and furthering research in autoimmune disease management.

Biomarkers are indispensable in assessing cardiovascular health and risk factors. Their use in early diagnosis, monitoring, and personalized treatment plans fuels the demand for biomarker technologies, leading to advancements in cardiovascular care and fostering market growth.

Breakup by Product:

  • Consumables
  • Assay
  • Reagent
  • Instruments

Consumables represent the leading market segment

Consumables, including sample collection kits and containers, are vital components of biomarker technology workflows. They are essential for collecting and preserving biological samples, making them indispensable for research, diagnostics, and drug development. The steady demand for these consumables ensures a consistent revenue stream in the biomarker technologies market.

Assays are at the heart of biomarker analysis. They encompass a wide range of techniques, such as ELISA and PCR, used to detect and quantify specific biomarkers. The development of innovative assay methods and kits further catalyzed market growth as they enable more precise and efficient biomarker detection.

Reagents are essential chemical compounds used in various stages of biomarker analysis. They play a critical role in sample preparation, labeling, and detection. The continuous need for high-quality reagents, especially for emerging biomarkers, fuels market demand, making reagents a lucrative segment.

Biomarker detection instruments, such as mass spectrometers and PCR machines, are the technological backbone of biomarker analysis. Advances in instrument capabilities, including sensitivity and throughput, significantly impact market growth. As research and diagnostic needs evolve, there has been a rise in the demand for cutting-edge biomarker detection instruments.

Breakup by Technology:

  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Immunoassay
  • Others

Immunoassay accounts for the majority of market share

Immunoassays are key for detecting protein biomarkers. They offer specificity, making them crucial in clinical diagnostics and research. Constant innovation in immunoassay platforms and reagents continues to propel the biomarker technologies market forward, enhancing biomarker detection sensitivity and precision.

Polymerase Chain Reaction (PCR) technology revolutionized biomarker analysis by enabling the amplification of DNA sequences. It plays a pivotal role in identifying genetic biomarkers, offering high specificity and sensitivity. Its versatility in applications, from disease diagnostics to gene expression analysis, ensures its enduring importance in the biomarker technologies market.

Next Generation Sequencing (NGS) technology enables comprehensive genomic and transcriptomic analysis. It contributes to biomarker discovery by identifying genetic variations associated with diseases. Its ability to process large datasets rapidly has accelerated research, making NGS a major driving force in biomarker-related advancements.

Breakup by Application:

  • Drug Discovery
  • Clinical Diagnostics
  • Personalized Medicine

Drug discovery represents the leading market segment

Biomarker technologies are indispensable in drug discovery, aiding in target identification, validation, and efficacy assessment. They streamline the drug development process by identifying potential therapeutic targets and predicting drug responses, reducing costs and accelerating time to market.

In clinical diagnostics, biomarkers play a pivotal role in disease diagnosis, prognosis, and treatment monitoring. Their use enhances healthcare by enabling early disease detection and personalized treatment plans, spurring the adoption of biomarker technologies in clinical settings, ultimately improving patient outcomes.

Biomarker technologies are the cornerstone of personalized medicine, allowing healthcare providers to tailor treatments based on individual patient profiles. This approach improves treatment efficacy, reduces adverse effects, and fosters patient-centric healthcare, thus fueling the growth of biomarker technologies in personalized medicine applications, revolutionizing healthcare delivery.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest biomarker technologies market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share since the region boasts a robust infrastructure, significant R&D investments, and a focus on healthcare innovation. The region's commitment to cutting-edge research and clinical applications positions it as a key driver of biomarker technology advancement.

Asia Pacific is also an expanding market for biomarker technologies owing to increasing healthcare investments, growing research capabilities, and a rising burden of chronic diseases. The region's emphasis on precision medicine and personalized healthcare drives demand for biomarker-based diagnostics and treatment strategies.

Europe's biomarker technologies market benefits from strong collaborations between academia and industry. It thrives on the continent's commitment to healthcare innovation, making it a prominent player in biomarker research and application development.

Biomarker technologies are rapidly gaining traction in the Middle East and Africa, supported by a growing demand for improved healthcare solutions. The region's increasing healthcare expenditure and heightened focus on disease prevention contribute to the adoption of biomarker-based diagnostics.

Latin America exhibits a growing biomarker technologies market, fueled by the rising prevalence of chronic diseases and a growing awareness of personalized medicine. The region's expanding healthcare infrastructure and research initiatives are driving the demand for biomarker-based solutions, making it a notable contributor to market growth.

LEADING KEY PLAYERS IN THE BIOMARKER TECHNOLOGIES INDUSTRY:

Various key players in the market are actively engaging innovation and strategic partnerships to maintain their competitive edge. They are also investing in research and development to enhance the sensitivity and specificity of biomarker detection methods. Additionally, these companies are expanding their product portfolios to cover a broader range of biomarkers and applications, catering to the growing demand for personalized medicine. Collaborations with academic institutions and pharmaceutical companies are common, fostering the discovery and validation of novel biomarkers. Moreover, these market leaders are focused on complying with regulatory standards to ensure the safety and effectiveness of their biomarker-based products, ultimately shaping the future of diagnostics and treatment in healthcare.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Illumina Inc.
  • LI-COR Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

Key Questions Answered in This Report:

  • How has the global biomarker technologies market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global biomarker technologies market?
  • What is the impact of each driver, restraint, and opportunity on the global biomarker technologies market?
  • What are the key regional markets?
  • Which countries represent the most attractive biomarker technologies market?
  • What is the breakup of the market based on the test type?
  • Which is the most attractive test type in the biomarker technologies market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the biomarker technologies market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the biomarker technologies market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the biomarker technologies market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the biomarker technologies market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global biomarker technologies market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biomarker Technologies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Test Type

  • 6.1 Solid Biopsy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Liquid Biopsy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Infectious Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Autoimmune Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular Disorders
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Product

  • 8.1 Consumables
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Assay
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Reagent
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Instruments
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Technology

  • 9.1 Polymerase Chain Reaction (PCR)
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Next Generation Sequencing (NGS)
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Immunoassay
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Application

  • 10.1 Drug Discovery
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinical Diagnostics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Personalized Medicine
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Agilent Technologies Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bio-Rad Laboratories Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Danaher Corporation
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 F. Hoffmann-La Roche AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Illumina Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 LI-COR Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
    • 16.3.7 Merck KGaA
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 PerkinElmer Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 QIAGEN N.V.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Shimadzu Corporation
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Thermo Fisher Scientific Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Waters Corporation
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Biomarker Technologies Market: Major Drivers and Challenges
  • Figure 2: Global: Biomarker Technologies Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Biomarker Technologies Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Biomarker Technologies Market: Breakup by Test Type (in %), 2025
  • Figure 5: Global: Biomarker Technologies Market: Breakup by Indication (in %), 2025
  • Figure 6: Global: Biomarker Technologies Market: Breakup by Product (in %), 2025
  • Figure 7: Global: Biomarker Technologies Market: Breakup by Technology (in %), 2025
  • Figure 8: Global: Biomarker Technologies Market: Breakup by Application (in %), 2025
  • Figure 9: Global: Biomarker Technologies Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Biomarker Technologies (Solid Biopsy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Biomarker Technologies (Solid Biopsy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Biomarker Technologies (Liquid Biopsy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Biomarker Technologies (Liquid Biopsy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Biomarker Technologies (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Biomarker Technologies (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Biomarker Technologies (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Biomarker Technologies (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Biomarker Technologies (Autoimmune Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Biomarker Technologies (Autoimmune Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Biomarker Technologies (Cardiovascular Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Biomarker Technologies (Cardiovascular Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Biomarker Technologies (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Biomarker Technologies (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Biomarker Technologies (Consumables) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Biomarker Technologies (Consumables) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Biomarker Technologies (Assay) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Biomarker Technologies (Assay) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Biomarker Technologies (Reagent) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Biomarker Technologies (Reagent) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Biomarker Technologies (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Biomarker Technologies (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Biomarker Technologies (Polymerase Chain Reaction - PCR) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Biomarker Technologies (Polymerase Chain Reaction - PCR) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Biomarker Technologies (Next Generation Sequencing - NGS) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Biomarker Technologies (Next Generation Sequencing - NGS) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Biomarker Technologies (Immunoassay) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Biomarker Technologies (Immunoassay) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Biomarker Technologies (Other Technologies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Biomarker Technologies (Other Technologies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Biomarker Technologies (Drug Discovery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Biomarker Technologies (Drug Discovery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Biomarker Technologies (Clinical Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Biomarker Technologies (Clinical Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Biomarker Technologies (Personalized Medicine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Biomarker Technologies (Personalized Medicine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: North America: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: North America: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: United States: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: United States: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Canada: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Canada: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Asia-Pacific: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Asia-Pacific: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: China: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: China: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Japan: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Japan: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: India: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: India: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: South Korea: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: South Korea: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Australia: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Australia: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Indonesia: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Indonesia: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Europe: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Europe: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Germany: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Germany: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: France: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: France: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: United Kingdom: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: United Kingdom: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Italy: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Italy: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Spain: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Spain: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Russia: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Russia: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Others: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Others: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Latin America: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Latin America: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Brazil: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Brazil: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Mexico: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Mexico: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Others: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Others: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Middle East and Africa: Biomarker Technologies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Middle East and Africa: Biomarker Technologies Market: Breakup by Country (in %), 2025
  • Figure 94: Middle East and Africa: Biomarker Technologies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 95: Global: Biomarker Technologies Industry: SWOT Analysis
  • Figure 96: Global: Biomarker Technologies Industry: Value Chain Analysis
  • Figure 97: Global: Biomarker Technologies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biomarker Technologies Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Biomarker Technologies Market Forecast: Breakup by Test Type (in Million USD), 2026-2034
  • Table 3: Global: Biomarker Technologies Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 4: Global: Biomarker Technologies Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 5: Global: Biomarker Technologies Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 6: Global: Biomarker Technologies Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 7: Global: Biomarker Technologies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Biomarker Technologies Market: Competitive Structure
  • Table 9: Global: Biomarker Technologies Market: Key Players